Liver transplant patients are at high risk for acute and chronic renal failure. Moreover, the introduction of the Model for End-Stage Liver Disease (MELD) scoring model can be used for the initial assignment of liver transplant patients with pre-transplant renal dysfunction insufficiency, who, after transplantation, are at higher risk of renal failure. Calcium-regulated phosphatase inhibitors (CNI) increase the risk of renal failure, so the use of morte-macrolide (MMF) may reduce the dosage of calcium-regulated phosphatase inhibitors and thus improve renal function. The combination of morte-mescaline with a low-dose calcium phosphatase inhibitor may be used early in transplantation (regimen 1) or in patients previously on a calcium phosphatase inhibitor-based immunosuppressive regimen who may switch to morte-mescaline in combination with a low-dose calcium phosphatase inhibitor or no calcium phosphatase inhibitor (regimen 2). Although many retrospective cohort studies and nonrandomized trials have demonstrated the effectiveness of this approach, the evidence from randomized controlled studies has not been summarized. In a recent review, we reported the results of a systematic review and meta-analysis of randomized controlled trials.